CompletedNot Applicable

Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes

United States6,180 participantsStarted 2023-05-01

Plain-language summary

The MIRON-PLATELET study is a retrospective, observational multi-center analysis assessing the impact of different antiplatelet therapies on hemorrhagic myocardial infarction (HMI) incidence and outcomes in STEMI patients. Key endpoints include hemorrhagic transformation, MACE, bleeding complications, and 30-day mortality. Findings will offer insights into the safety and clinical implications of antiplatelet therapy in high-risk patients.

Who can participate

Age range18 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18-79 years at the time of STEMI diagnosis
✓. Diagnosed with ST-segment elevation myocardial infarction (STEMI) based on standard clinical criteria
✓. Received antiplatelet therapy as part of STEMI management
✓. Underwent primary percutaneous coronary intervention (PCI)
✓. Evidence of hemorrhagic MI confirmed by Cardiac Magnetic Resonance Imaging OR Post-PCI biomarker diagnostics
✓. Availability of comprehensive medical records documenting STEMI presentation, treatment details, and clinical outcomes
✓. Minimum of 30-day follow-up data, with extended follow-up available for up to 10 years

Exclusion criteria

✕. Diagnosis of non-STEMI (NSTEMI), unstable angina, or other non-ischemic cardiomyopathies
✕. History of prior hemorrhagic stroke or active intracranial bleeding before the index STEMI event
✕. Known bleeding disorders (e.g., hemophilia, thrombocytopenia \<50,000/µL)
✕. Use of chronic antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel) before STEMI diagnosis
✕. Use of long-term anticoagulation therapy (warfarin, DOACs such as apixaban, rivaroxaban, dabigatran) before STEMI diagnosis

What they're measuring

Incidence of Hemorrhagic Myocardial Infarction (HMI) in STEMI Patients Receiving Different Antiplatelet Therapies

Timeframe: 30 days post-STEMI diagnosis

Trial details

NCT IDNCT06851325

SponsorRohan Dharmakumar

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-30

View on ClinicalTrials.gov More STEMI trials